Geode Capital Management LLC Purchases 211,475 Shares of Codexis, Inc. (NASDAQ:CDXS)

Geode Capital Management LLC lifted its holdings in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 12.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,855,514 shares of the biotechnology company's stock after acquiring an additional 211,475 shares during the quarter. Geode Capital Management LLC owned approximately 2.28% of Codexis worth $8,853,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Kingswood Wealth Advisors LLC bought a new position in Codexis during the fourth quarter worth $79,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Codexis in the fourth quarter valued at $82,000. Intech Investment Management LLC increased its holdings in shares of Codexis by 55.1% in the fourth quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 11,757 shares during the last quarter. Corebridge Financial Inc. increased its holdings in shares of Codexis by 7.2% in the fourth quarter. Corebridge Financial Inc. now owns 40,052 shares of the biotechnology company's stock valued at $191,000 after purchasing an additional 2,703 shares during the last quarter. Finally, Jackson Square Capital LLC acquired a new position in shares of Codexis in the fourth quarter valued at $210,000. 78.54% of the stock is owned by institutional investors and hedge funds.

Codexis Stock Performance

Shares of NASDAQ:CDXS remained flat at $2.33 on Tuesday. 335,528 shares of the company's stock traded hands, compared to its average volume of 660,876. Codexis, Inc. has a 12-month low of $1.90 and a 12-month high of $6.08. The company has a market cap of $193.01 million, a PE ratio of -2.68 and a beta of 2.35. The stock's fifty day moving average is $2.65 and its 200 day moving average is $3.81. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The business had revenue of $21.46 million during the quarter, compared to analyst estimates of $27.41 million. Sell-side analysts anticipate that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.